DK0536363T3 - Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf - Google Patents

Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf

Info

Publication number: DK0536363T3
Authority: DK; Denmark
Prior art keywords: heparin; show; equal; new; processes
Prior art date: 1991-04-18

Application number

DK92908867.2T

Other languages

English (en)

Inventor

Crister Mattsson

Michael Weber

Carl-Magnus Svahn

Original Assignee

Pharmacia & Upjohn Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-18

Filing date

1992-04-14

Publication date

1998-01-26

1992-04-14 Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab

1998-01-26 Application granted granted Critical

1998-01-26 Publication of DK0536363T3 publication Critical patent/DK0536363T3/da

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 8
239000002628 heparin derivative Substances 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
229960002897 heparin Drugs 0.000 abstract 5
229920000669 heparin Polymers 0.000 abstract 5
241000283690 Bos taurus Species 0.000 abstract 2
229940064551 bovine heparin Drugs 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
229940045627 porcine heparin Drugs 0.000 abstract 2
241000282472 Canis lupus familiaris Species 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
230000000740 bleeding effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1
230000014508 negative regulation of coagulation Effects 0.000 abstract 1
230000010412 perfusion Effects 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Materials Engineering (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Polymers & Plastics (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DK92908867.2T 1991-04-18 1992-04-14 Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf DK0536363T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9101155A SE9101155D0 (sv)	1991-04-18	1991-04-18	Novel heparin derivatives

Publications (1)

Publication Number	Publication Date
DK0536363T3 true DK0536363T3 (da)	1998-01-26

Family

ID=20382487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK92908867.2T DK0536363T3 (da)	1991-04-18	1992-04-14	Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf

Country Status (12)

Country	Link
US (2)	US6150342A (da)
EP (1)	EP0536363B1 (da)
JP (1)	JP3278676B2 (da)
AT (1)	ATE154614T1 (da)
AU (1)	AU642626B2 (da)
CA (1)	CA2084301C (da)
DE (1)	DE69220442T2 (da)
DK (1)	DK0536363T3 (da)
ES (1)	ES2104909T3 (da)
GR (1)	GR3024757T3 (da)
SE (1)	SE9101155D0 (da)
WO (1)	WO1992018545A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5696100A (en) *	1992-12-22	1997-12-09	Glycomed Incorporated	Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) *	1992-12-22	1994-03-22	Glycomed Incorporated	Method for controlling o-desulfation of heparin and compositions produced thereby
WO1995030424A1 (en) *	1994-05-06	1995-11-16	Glycomed Incorporated	O-desulfated heparin derivatives, methods of making and uses thereof
WO1996024362A1 (fr) *	1995-02-07	1996-08-15	Shiseido Company, Ltd.	Agents anti-inflammatoires
US5763427A (en) *	1995-03-31	1998-06-09	Hamilton Civic Hospitals Research Development Inc.	Compositions and methods for inhibiting thrombogenesis
US6001820A (en) *	1995-03-31	1999-12-14	Hamilton Civic Hospitals Research Development Inc.	Compositions and methods for inhibiting thrombogenesis
US5744457A (en) *	1995-03-31	1998-04-28	Hamilton Civic Hospitals Research Development Inc.	Compositions and methods for inhibiting thrombogenesis
US5767269A (en) *	1996-10-01	1998-06-16	Hamilton Civic Hospitals Research Development Inc.	Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1999043714A1 (fr) *	1998-02-26	1999-09-02	Seikagaku Corporation	Nouveaux derives de polysaccharide, leur procede de production, et compositions medicinales contenant ces nouveaux derives comme principe actif
KR20020032444A (ko) *	1999-06-30	2002-05-03	잭 허쉬	응괴 연관된 응고 인자를 억제하는 헤파린 조성물
US7608246B2 (en) *	2005-09-02	2009-10-27	The Brigham And Women's Hospital, Inc.	Apolipoprotein E as an adjuvant for lipid antigens
US8569262B2 (en)	2007-11-02	2013-10-29	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) *	2007-11-02	2016-04-19	Momenta Pharmaceuticals, Inc.	Composiciones de polisacáridos que no son anticoagulantes
US8592393B2 (en)	2007-11-02	2013-11-26	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
BR112012026542A2 (pt)	2010-04-16	2016-07-12	Momenta Pharmaceuticals Inc	abordagem seletiva de tecido
JP5905455B2 (ja)	2010-06-17	2016-04-20	モメンタファーマシューティカルズインコーポレイテッド	発毛を促進する方法および組成物
WO2014193818A1 (en)	2013-05-28	2014-12-04	Momenta Pharmaceuticals, Inc.	Pharmaceutical compositions
GB2515315A (en) *	2013-06-19	2014-12-24	Dilafor Ab	New Processes
WO2022015794A1 (en)	2020-07-14	2022-01-20	Optimvia, Llc	Methods for synthesizing non-anticoagulant heparan sulfate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1136620A (en) *	1979-01-08	1982-11-30	Ulf P.F. Lindahl	Heparin fragments having selective anticoagulation activity
IL61201A (en) *	1979-10-05	1984-09-30	Choay Sa	Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4948881A (en) *	1982-12-28	1990-08-14	Sanofi	Process for the depolymerization and sulfation of polysaccharides
FR2538404B1 (da) *	1982-12-28	1985-08-23	Anic Spa
US4745098A (en) *	1984-02-24	1988-05-17	The Regents Of The University Of California	Compositions and method for improving wound healing
FR2584728B1 (fr) *	1985-07-12	1987-11-20	Choay Sa	Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2614026B1 (fr) *	1987-04-16	1992-04-17	Sanofi Sa	Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) *	1987-05-29	1987-05-29	Kabivitrum Ab	Novel heparin derivatives
DE3744119A1 (de) *	1987-12-24	1989-07-06	Basf Ag	Verwendung von polysulfatierten heparinen
IT1237518B (it) *	1989-11-24	1993-06-08	Renato Conti	Eparine supersolfatate

1991
- 1991-04-18 SE SE9101155A patent/SE9101155D0/xx unknown
1992
- 1992-04-14 DE DE69220442T patent/DE69220442T2/de not_active Expired - Fee Related
- 1992-04-14 DK DK92908867.2T patent/DK0536363T3/da active
- 1992-04-14 AT AT92908867T patent/ATE154614T1/de not_active IP Right Cessation
- 1992-04-14 CA CA002084301A patent/CA2084301C/en not_active Expired - Fee Related
- 1992-04-14 JP JP50809992A patent/JP3278676B2/ja not_active Expired - Fee Related
- 1992-04-14 US US07/949,551 patent/US6150342A/en not_active Expired - Fee Related
- 1992-04-14 AU AU16463/92A patent/AU642626B2/en not_active Ceased
- 1992-04-14 ES ES92908867T patent/ES2104909T3/es not_active Expired - Lifetime
- 1992-04-14 EP EP92908867A patent/EP0536363B1/en not_active Expired - Lifetime
- 1992-04-14 WO PCT/SE1992/000243 patent/WO1992018545A1/en active IP Right Grant
1995
- 1995-05-10 US US08/438,933 patent/US6326476B1/en not_active Expired - Fee Related
1997
- 1997-09-17 GR GR970402402T patent/GR3024757T3/el unknown

Also Published As

Publication number	Publication date
CA2084301C (en)	2005-10-25
JP3278676B2 (ja)	2002-04-30
DE69220442D1 (de)	1997-07-24
ES2104909T3 (es)	1997-10-16
CA2084301A1 (en)	1992-10-19
ATE154614T1 (de)	1997-07-15
EP0536363B1 (en)	1997-06-18
AU1646392A (en)	1992-11-17
DE69220442T2 (de)	1998-01-29
GR3024757T3 (en)	1997-12-31
US6150342A (en)	2000-11-21
EP0536363A1 (en)	1993-04-14
WO1992018545A1 (en)	1992-10-29
JPH05508184A (ja)	1993-11-18
US6326476B1 (en)	2001-12-04
SE9101155D0 (sv)	1991-04-18
AU642626B2 (en)	1993-10-21

Similar Documents

Publication	Publication Date	Title
DK0536363T3 (da)	1998-01-26	Hidtil ukendte heparinderivater og fremgangsmåde til fremstilling deraf
ATE87319T1 (de)	1993-04-15	Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
RU93054168A (ru)	1996-10-10	Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
ATE153346T1 (de)	1997-06-15	Oxidationsresistente analoga des thrombomodulins
ATE161273T1 (de)	1998-01-15	Polysaccharidderivate von heparin, heparansulfate, ihre fraktionen und fragmente, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, welche diese enthalten
IT1230582B (it)	1991-10-28	Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
ATE224918T1 (de)	2002-10-15	Zusammensetzung zur hemmung der thromboseentstehung
JPH09510736A (ja)	1997-10-28	ヘパリンをベースとした抗血栓性で非出血性の組成物と、その調製方法と、治療への利用
DK0462194T3 (da)	1994-09-19	Fibroblastvækstfaktor-(FGF)-baserede stabiliserede sammensætninger
ES2174838T3 (es)	2002-11-16	Metodo para aumentar la absorcion del intestino.
RU2216548C2 (ru)	2003-11-20	Смесь линейных олигосахаридов, полученная из дерматансульфата, фармацевтическая композиция, обладающая антитромботическим действием, и способ лечения
DE69025691D1 (de)	1996-04-11	Einschlusskomplexe mit Silybinin, ihre Herstellung und pharmazeutische Präparate, die diese enthalten
Woods et al.	1986	Antithrombotic therapy in children and adolescents
KR930012023A (ko)	1993-07-20	환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR910001040A (ko)	1991-01-30	항응고요법을 위한 활성물질인 암블리옴민
DE4430204A1 (de)	1996-02-29	Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
WO2001036462A3 (en)	2001-11-22	Protein c derivatives
JPS63233927A (ja)	1988-09-29	ウロキナーゼ阻害剤
FR2380275A1 (fr)	1978-09-08	Nouveaux composes imidazoles et leurs derives sulfoxydes et sulfones correspondants, leur preparation et compositions pharmaceutiques les contenant
ATE112276T1 (de)	1994-10-15	Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
Borowska et al.	1988	Impairment of primary haemostasis by low molecular weight heparins in rats
SU1695929A1 (ru)	1991-12-07	Способ лечени инфаркта миокарда
Czuba	1972	Antithrombotic Agents
Ohara et al.	1966	Anticoagulative activity of ω-heparin in the intramuscular application
LARSEN et al.	1978	SOME PHYSIOLOGICAL EFFECTS OF FRACTIONATED JELLYFISH TOXIN